Biomaterial Platform for Advancing the Supply Chain of Cell and Gene Therapies |
|
About TheraBoostTheraBoost is developing an engineered biomaterial platform to address critical challenges in the supply chain of cell and gene therapies (CGTs). By leveraging the unique properties of rationally designed biomaterials, TheraBoost aims to improve the manufacturing, transport, and scalability of these advanced therapies.
Our goal is to ensure that life-saving CGTs, which are rapidly emerging as transformative treatments for severe diseases and regenerative medicine, can reach patients more reliably, efficiently, and at scale, while aligning with Portuguese and European innovation priorities. |
Why TheraBoost?
|
The CGT supply chain is complex and fragile, requiring careful coordination across all stages from cell collection to patient delivery. Even small losses in cell viability during manufacturing or transport can jeopardize treatment success, increase costs, and limit patient access. To illustrate these challenges, the diagram below shows the fragmented journey of CGTs, from clinical sites to manufacturers and couriers, and the corresponding TheraBoost’s intervention points. 
|
What We Aim to Achieve
|
The TheraBoost project is advancing three biomaterial-based innovations to tackle critical challenges in manufacturing and delivery of CGTs: |
Cell Engineering Platform
A biomaterial-based platform designed to enable more efficient and reliable cell modification.
This aims to overcome the current inefficiencies in genetic modification, advancing personalised medicine and boosting the effectiveness of engineered CGT products. |
Cell Expansion Microcarriers
Next-generation microcarriers that enable high-quality cell expansion while promoting sustainable manufacturing.
The adoption of degradable and eco-friendly materials aims to reduce plastic waste and improve energy efficiency compared to standard methods. |
Hypothermic Shipping Matrix
A novel transport solution for viable cells, eliminating the need for cryopreservation.
This approach reduces greenhouse gas emissions, lowers energy use and costs, and supports a more sustainable CGT supply chain. |
|
|
Stemmatters is a Contract Development and Manufacturing Organisation (CDMO) specialised in regenerative medicine. Stemmatters focuses on product and process development, cGMP production, and the clinical translation of advanced medicinal products.
With a multidisciplinary team, Stemmatters is uniquely positioned to ensure the technical and commercial success of TheraBoost, paving the way for a more accessible and sustainable future in CGTs. |
Subscribe to our Newsletter |
|
Sign up with your email address to receive news and updates about TheraBoost |
|
|
